The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations.
 
Michael Iglesia
No Relationships to Disclose
 
Moh'd M. Khushman
Stock and Other Ownership Interests - Blueprint Medicines; Cardiff Oncology; Moderna Therapeutics; Regeneron
Consulting or Advisory Role - AstraZeneca; Bayer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Caris Life Sciences; Pfizer
 
Kian-Huat Lim
Honoraria - Jacobio
Research Funding - Aclaris Therapeutics
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Jingxia Liu
No Relationships to Disclose
 
Katrina Sophia Pedersen
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; GlaxoSmithKline; Novartis; Pfizer; SAGA Diagnostics; Taiho Oncology
Speakers' Bureau - Clinical Care Options; WebMD
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Daiichi Sankyo/Lilly (Inst); HCW Biologics (Inst); Incyte (Inst); Ipsen (Inst); Merck (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Array BioPharma; BeiGene; Nouscom
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - NCCN
 
Xiuli Liu
No Relationships to Disclose
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
Rama Suresh
No Relationships to Disclose
 
Olivia Aranha
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (Inst)
 
Patrick Grierson
Employment - Walgreens (I)
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Benjamin R. Tan
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); TYME (Inst)
 
Ramaswamy Govindan
Consulting or Advisory Role - Jacobio; Merck; Precisca